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Purpose or Objective: To investigate the impact of tumour 
volume, hypoxia and cancer stem cell (CSC) marker 
expression on outcome of patients with locally advanced 
head and neck squamous cell carcinoma (HNSCC) after 
primary radiochemotherapy.  
 
Material and Methods: In this retrospective multicentre 
study, 160 patients with squamous cell carcinoma of the oral 
cavity, oropharynx and hypopharynx were included. All 
patients received primary cisplatin-based radiochemotherapy 
(RCT) between 2005 and 2011. Their median follow-up was 
about 26 months. Primary and nodal gross tumour volume 
(GTV) segmentations were performed centrally in the 
computer tomography-based radiation treatment plans. HPV 
status (p16 overexpression) and CD44 expression were 
analysed by immunohistochemistry. Gene expression analysis 
was performed for hypoxia-associated genes and the 
potential CSC marker SLC3A2. Results of the biomarker 
analyses, clinical parameters and tumour volume were 
correlated with the clinical outcome. Primary endpoint was 
loco-regional control (LRC). Secondary endpoints were 
distant metastases (DM) and overall survival (OS).  
 
Results: In univariate analysis, tumour volume, HPV status 
and CSC marker expression were significantly associated with 
LRC (tumour volume: HR 1.51, p=0.02; HPV: HR 0.30, p=0.02; 
CD44: HR 2.30, p=0.04; SLC3A2: HR 2.08, p=0.01). 
Interestingly, hypoxia showed a significant association with 
LRC in small tumours only (HR 9.26, p=0.04). Multivariate Cox 
regression analysis including HPV status, tumour localisation, 
stage, smoking status, tumour volume and hypoxia or the 
respective CSC marker showed a significant effect of the 
tumour volume (HR: 1.6-1.8, p<0.01), SLC3A2 (HR 2.03, 
p=0.02) or CD44 (HR 2.52, p=0.04) on LRC. Tumour hypoxia 
also reached borderline significance in small tumours (HR 
7.86, p=0.06). Interestingly, the tumour volume was an 
independent variable in all Cox models, a high tumour 
volume was significantly associated with poor LRC. Tumour 
volume and CSC marker expression also showed a negative 
prognostic impact on the secondary endpoints DM and OS.  
 
Conclusion: We have shown that large tumour volume and 
high CSC marker expression correlate with poor LRC in 
patients with locally advanced HNSCC who received primary 
RCT. In small tumours, hypoxia also had a negative impact. 
After validation of these promising results in the ongoing 
prospective study of our study group, these biomarkers may 
help to further stratify patients for individualised treatment 
escalation or de-escalation strategies. 
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Purpose or Objective: A multicentre prospective randomized 
phase II trial investigated whether a 3-phase adaptive IMRT-
scheme using reduced volumes of elective neck could reduce 
toxicity without compromising disease control compared to 
standard non-adaptive IMRT. We report on disease control 
and toxicity at 6 and 12 months of follow-up. 
 
Material and Methods: All patients were primarily treated 
with IMRT ± chemotherapy for head and neck squamous cell 
carcinoma with a 2 Gy-equivalent dose of 40 Gy to the 
elective neck. The dose to the high-risk volume was not 
reduced. In the adaptive de-escalation (AD) arm, elective 
neck volumes were reduced based on a lower theoretical risk 
of subclinical disease and replanning was done after 2 and 4 
weeks. In the control (C) arm, IMRT without adaptations and 
with standard volumes of elective neck was performed.  
All statistics were performed using Fisher’s exact test and 
Kaplan-Meier analysis (SPSS v. 23). 
 
Results: Patiënts, tumor and treatment characteristics can 
be found in Table 1.  
Before 1 year of follow-up, 12 patients deceased due to 
aspiration (n=1), tumor progression (n=8) or intercurrent 
disease (n=3).  
At 6 months, we observed grade (G)≥2 dysphagia in 3% and 6% 
(p = 1.0), G≥2 xerostomia in 40% and 34% (p = 0.81) and G≥2 
fibrosis in 6% and 6% (p = 1.0) in the AD- and C-arm, 
respectively. At 12 months, we observed grade G≥2 dysphagia 
in 17% and 3% (p = 0.09), G≥2 xerostomia in 43% and 28% (p = 
0.28) and G≥2 fibrosis in 10% and 9% (p = 1.0) in the AD- and 
C-arm, respectively.  
Local (LC), regional (RC) and distant control (DC) and overall 
survival (OS) for the whole group are given in Fig. 1. LC, RC, 
DC and OS were 86%, 84%, 82% and 74% in the AD-arm and 
90%, 92%, 86% and 78% in the C-arm, respectively. All p-
values were > 0.05. Regional relapse was observed in 8 (AD) 
and 4 (C) patients: 5/12 were isolated regional relapses (3 in 
the AD- and 2 in the C-arm) of which 3/5 isolated relapses 
were seen in the initial GTV of a pathological lymph node, 
1/5 in the irradiated elective neck in the C-arm and 1/5 in 
the AD-arm in a region of the neck that would have been 
irradiated in the C-arm; salvage neck dissection was 
successfully performed. Seven regional relapses were 





Conclusion: With a minimal follow-up of 1 year, no 
significant differences in RC, LC or DC or OS were observed 
between adaptive IMRT with reduced volumes of elective 
neck versus standard IMRT with non-reduced volumes, 
although 1 patient had an isolated regional recurrence in the 
non-treated elective neck. Unfortunately, the volume 
reduction and adaptive strategy did not result in a better late 
toxicity profile. We hypothesize that due to the large portion 
of patients with locoregionally advanced disease the treated 
neck volumes could not be sufficiently reduced in the whole 
group to achieve the desired gain in toxicity. Future analysis 
will now be started to elucidate this problem. 
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Purpose or Objective: We performed a prospective multi-
institutional phase II study of a substantial decrease in 
concurrent chemoradiotherapy (CRT) intensity as primary 
treatment for favorable risk, HPV-associated oropharyngeal 
squamous cell carcinoma (OPSCC). 
 
Material and Methods: The major inclusion criteria were: 1) 
T0-T3, N0-N2c, M0, 2) HPV or p16 positive, and 3) 
minimal/remote smoking history. Treatment was limited to 
60 Gy intensity modulated radiotherapy with concurrent 
weekly intravenous cisplatinum (30 mg/m2). The primary 
study endpoint was pathologic complete response rate (pCR) 
based on required biopsy of the primary site and dissection of 
pretreatment positive lymph node regions, regardless of 
radiographic response. Power computations were performed 
for the null hypothesis that the pCR rate is 87% and N=40, 
resulting in a type I error of 14.2%. Secondary endpoint 
measures included physician reported toxicity (CTCAE), 
patient reported symptoms (PRO-CTCAE), quality of life 
